Hund E, Singer R, Linke R P, Willig F, Grau A
Neurologische Universitätsklinik Heidelberg, Germany.
Nervenarzt. 2002 Oct;73(10):930-6. doi: 10.1007/s00115-002-1345-9.
Hereditary amyloidoses form a clinically and genetically heterogeneous group of autosomal-dominantly inherited diseases characterized by the ubiquitous extracellular deposit of fibrillary aggregated proteins. Main components of these unsolvable deposits are physiologic proteins that became amyloidogenic through genetically determined conformation changes resulting in an increase in beta-sheet structures. In the vast majority of cases, the offending protein is variant transthyretin (TTR), of which over 80 mutations are known. Among these, substitution of valine by methionine in position 30 (TTR-Met30) is the most commonly encountered. In typical cases, TTR amyloidoses present with polyneuropathy, carpal tunnel syndrome, autonomic insufficiency, cardiomyopathy, and gastrointestinal features, occasionally accompanied by vitreous opacities and renal insufficiency. Rarely, involvement of the leptomeningeal or meningovascular structures dominates the clinical picture. The clinical expression is highly variable, with many atypical manifestations. Asymptomatic mutations have recently been identified. The age of onset varies greatly between early adulthood and old age. Late-onset atypical manifestations and occurrence of asymptomatic carriers render identification of affected family members difficult despite autosomal-dominant inheritance. Orthotopic liver transplantation (OLT) is the only effective therapy available today. This OLT stops progression of the disease, which is otherwise invariably fatal, by removal of the main production site of the amyloidogenic protein. However, cardiac involvement may progress after OLT for unknown reasons. The indication for OLT and its success depend on the grade of cardiovascular and autonomic dysfunction at the time of surgery, age, comorbidity, and type of mutation. Alternative treatment modalities with drugs stabilizing the native tetrameric conformation of TTR, inhibiting fibril formation or breaking beta-sheet structures, are currently being intensively studied.
遗传性淀粉样变性是一组临床和遗传异质性的常染色体显性遗传病,其特征是纤维状聚集蛋白在细胞外广泛沉积。这些不可溶性沉积物的主要成分是生理蛋白,它们通过基因决定的构象变化而变成淀粉样蛋白,导致β-折叠结构增加。在绝大多数情况下,致病蛋白是变异型转甲状腺素蛋白(TTR),已知有80多种突变。其中,第30位缬氨酸被甲硫氨酸取代(TTR-Met30)最为常见。在典型病例中,TTR淀粉样变性表现为多发性神经病、腕管综合征、自主神经功能不全、心肌病和胃肠道症状,偶尔伴有玻璃体混浊和肾功能不全。很少见的是,软脑膜或脑膜血管结构受累在临床表现中占主导。临床表型高度可变,有许多非典型表现。最近发现了无症状突变。发病年龄在成年早期和老年之间差异很大。尽管是常染色体显性遗传,但迟发性非典型表现和无症状携带者的出现使得识别受影响的家庭成员变得困难。原位肝移植(OLT)是目前唯一有效的治疗方法。这种OLT通过去除淀粉样蛋白生成蛋白的主要产生部位,阻止了疾病的进展,否则疾病将不可避免地致命。然而,OLT后心脏受累可能因不明原因而进展。OLT的指征及其成功率取决于手术时心血管和自主神经功能障碍的程度、年龄、合并症和突变类型。目前正在深入研究用药物稳定TTR的天然四聚体构象、抑制纤维形成或破坏β-折叠结构的替代治疗方式。